Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE